Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 7/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL964097 | 1.00 | MEN1 (0.39) | MEN1GALR3KMT2APTGER4PTGER2 | |
| SCHEMBL964095 | 1.00 | MEN1 (0.39) | MEN1GALR3KMT2APTGER4PTGER2 | |
| SCHEMBL961642 | 0.83 | MEN1 (0.46) | MEN1GALR3KMT2APTGER4PTGER2 | |
| SCHEMBL964416 | 0.83 | MEN1 (0.46) | MEN1GALR3KMT2APTGER4PTGER2 | |
| SCHEMBL961640 | 0.83 | MEN1 (0.46) | MEN1GALR3KMT2APTGER4PTGER2 | |
| SCHEMBL10703299 | 0.78 | PTGIR (0.34) | PTGER4PTGER2PTGER3 | |
| SCHEMBL10952197 | 0.76 | PTGDR2 (0.36) | PTGER4PTGER2PTGER3 | |
| SCHEMBL11509792 | 0.75 | MEN1 (0.42) | MEN1GALR3KMT2APTGER4PTGER2 | |
| SCHEMBL11509790 | 0.75 | MEN1 (0.42) | MEN1GALR3KMT2APTGER4PTGER2 | |
| SCHEMBL14514295 | 0.75 | MEN1 (0.59) | MEN1GALR3KMT2APTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501793-B2 | Blood flow promoters for cauda equina tissues | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20110015238-A1 | BLOOD FLOW PROMOTERS FOR CAUDA EQUINA TISSUES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| US-7833995-B2 | Blood flow promoters for cauda equina tissues | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20070129327-A1 | Blood flow promoters for cauda equina tissues | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1707208-A1 | BLOOD FLOW PROMOTERS FOR CAUDA EQUINA TISSUES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129327-A1 | Blood flow promoters for cauda equina tissues | PTGFR, PTGIS, PTGIR | MEN1 4761/4885GALR3 1295/4885KMT2A 1776/4885 |
| US-20110015238-A1 | BLOOD FLOW PROMOTERS FOR CAUDA EQUINA TISSUES | PTGFR, PTGIS, PTGIR | MEN1 4761/4885GALR3 1295/4885KMT2A 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.